Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis

INTRODUCTION: Anti-RNA polymerase III (a-RNA Pol III) antibodies are marker antibodies in patients with systemic sclerosis (SSc). AIM: To assess the prevalence of a-RNA Pol III in patients with SSc and to identify the differences in the disease picture in SSc patients with and without a-RNA Pol III...

Descripción completa

Detalles Bibliográficos
Autores principales: Wielosz, Ewa, Dryglewska, Magdalena, Majdan, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874867/
https://www.ncbi.nlm.nih.gov/pubmed/33603608
http://dx.doi.org/10.5114/ada.2020.102107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874867/
https://www.ncbi.nlm.nih.gov/pubmed/33603608
http://dx.doi.org/10.5114/ada.2020.102107

Ejemplares similares